vs

Side-by-side financial comparison of FREQUENCY ELECTRONICS INC (FEIM) and Alpha Teknova, Inc. (TKNO). Click either name above to swap in a different company.

FREQUENCY ELECTRONICS INC is the larger business by last-quarter revenue ($17.1M vs $10.0M, roughly 1.7× Alpha Teknova, Inc.). FREQUENCY ELECTRONICS INC runs the higher net margin — 10.5% vs -47.7%, a 58.2% gap on every dollar of revenue. On growth, FREQUENCY ELECTRONICS INC posted the faster year-over-year revenue change (8.3% vs 7.8%). Alpha Teknova, Inc. produced more free cash flow last quarter ($-810.0K vs $-1.1M). Over the past eight quarters, FREQUENCY ELECTRONICS INC's revenue compounded faster (11.8% CAGR vs 3.7%).

Ultra Electronics Holdings is a British defence and security company. It was listed on the London Stock Exchange and was a constituent of the FTSE 250 Index until it was acquired by Cobham, which is itself owned by Advent International.

Alpha Teknova, Inc. is a life sciences company that develops and manufactures specialized reagents, cell culture media, and custom laboratory solutions. It serves biopharmaceutical, molecular diagnostic, and academic research clients, primarily operating across the North American market to support drug discovery, diagnostic testing, and life science research workflows.

FEIM vs TKNO — Head-to-Head

Bigger by revenue
FEIM
FEIM
1.7× larger
FEIM
$17.1M
$10.0M
TKNO
Growing faster (revenue YoY)
FEIM
FEIM
+0.5% gap
FEIM
8.3%
7.8%
TKNO
Higher net margin
FEIM
FEIM
58.2% more per $
FEIM
10.5%
-47.7%
TKNO
More free cash flow
TKNO
TKNO
$326.0K more FCF
TKNO
$-810.0K
$-1.1M
FEIM
Faster 2-yr revenue CAGR
FEIM
FEIM
Annualised
FEIM
11.8%
3.7%
TKNO

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
FEIM
FEIM
TKNO
TKNO
Revenue
$17.1M
$10.0M
Net Profit
$1.8M
$-4.8M
Gross Margin
38.2%
32.5%
Operating Margin
10.0%
-46.2%
Net Margin
10.5%
-47.7%
Revenue YoY
8.3%
7.8%
Net Profit YoY
-32.1%
16.8%
EPS (diluted)
$0.18
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FEIM
FEIM
TKNO
TKNO
Q4 25
$17.1M
$10.0M
Q3 25
$13.8M
$10.5M
Q2 25
$20.0M
$10.3M
Q1 25
$18.9M
$9.8M
Q4 24
$15.8M
$9.3M
Q3 24
$15.1M
$9.6M
Q2 24
$15.6M
$9.6M
Q1 24
$13.7M
$9.3M
Net Profit
FEIM
FEIM
TKNO
TKNO
Q4 25
$1.8M
$-4.8M
Q3 25
$634.0K
$-4.3M
Q2 25
$3.2M
$-3.6M
Q1 25
$15.4M
$-4.6M
Q4 24
$2.7M
$-5.7M
Q3 24
$2.4M
$-7.6M
Q2 24
$2.6M
$-5.4M
Q1 24
$130.0K
$-8.1M
Gross Margin
FEIM
FEIM
TKNO
TKNO
Q4 25
38.2%
32.5%
Q3 25
36.8%
30.7%
Q2 25
37.5%
38.7%
Q1 25
43.8%
30.7%
Q4 24
48.2%
23.0%
Q3 24
44.4%
0.9%
Q2 24
40.3%
29.2%
Q1 24
22.6%
23.8%
Operating Margin
FEIM
FEIM
TKNO
TKNO
Q4 25
10.0%
-46.2%
Q3 25
2.6%
-38.4%
Q2 25
16.4%
-32.9%
Q1 25
18.3%
-50.7%
Q4 24
16.5%
-60.7%
Q3 24
15.7%
-77.6%
Q2 24
16.0%
-53.0%
Q1 24
-3.4%
-86.0%
Net Margin
FEIM
FEIM
TKNO
TKNO
Q4 25
10.5%
-47.7%
Q3 25
4.6%
-41.0%
Q2 25
16.0%
-34.7%
Q1 25
81.4%
-47.4%
Q4 24
16.8%
-61.7%
Q3 24
16.1%
-79.0%
Q2 24
16.9%
-55.8%
Q1 24
0.9%
-87.2%
EPS (diluted)
FEIM
FEIM
TKNO
TKNO
Q4 25
$0.18
$-0.08
Q3 25
$0.07
$-0.08
Q2 25
$0.33
$-0.07
Q1 25
$1.60
$-0.09
Q4 24
$0.28
$-0.09
Q3 24
$0.25
$-0.15
Q2 24
$0.28
$-0.13
Q1 24
$0.01
$-0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FEIM
FEIM
TKNO
TKNO
Cash + ST InvestmentsLiquidity on hand
$3.0M
$21.3M
Total DebtLower is stronger
$13.1M
Stockholders' EquityBook value
$58.5M
$68.8M
Total Assets
$92.3M
$103.6M
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FEIM
FEIM
TKNO
TKNO
Q4 25
$3.0M
$21.3M
Q3 25
$4.5M
$22.1M
Q2 25
$4.7M
$24.0M
Q1 25
$5.5M
$26.3M
Q4 24
$9.7M
$30.4M
Q3 24
$16.2M
$31.7M
Q2 24
$18.3M
$18.6M
Q1 24
$11.7M
$21.6M
Total Debt
FEIM
FEIM
TKNO
TKNO
Q4 25
$13.1M
Q3 25
$13.1M
Q2 25
$13.0M
Q1 25
$13.0M
Q4 24
$9.4M
Q3 24
$10.9M
Q2 24
$12.3M
Q1 24
$13.2M
Stockholders' Equity
FEIM
FEIM
TKNO
TKNO
Q4 25
$58.5M
$68.8M
Q3 25
$56.3M
$72.7M
Q2 25
$55.6M
$76.1M
Q1 25
$51.8M
$78.6M
Q4 24
$36.2M
$82.4M
Q3 24
$33.2M
$87.3M
Q2 24
$39.8M
$78.9M
Q1 24
$36.7M
$83.4M
Total Assets
FEIM
FEIM
TKNO
TKNO
Q4 25
$92.3M
$103.6M
Q3 25
$93.2M
$107.6M
Q2 25
$93.7M
$110.5M
Q1 25
$86.4M
$114.0M
Q4 24
$77.8M
$118.8M
Q3 24
$84.3M
$124.1M
Q2 24
$83.3M
$115.4M
Q1 24
$77.7M
$120.8M
Debt / Equity
FEIM
FEIM
TKNO
TKNO
Q4 25
0.19×
Q3 25
0.18×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.11×
Q3 24
0.12×
Q2 24
0.16×
Q1 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FEIM
FEIM
TKNO
TKNO
Operating Cash FlowLast quarter
$-523.0K
$-462.0K
Free Cash FlowOCF − Capex
$-1.1M
$-810.0K
FCF MarginFCF / Revenue
-6.6%
-8.1%
Capex IntensityCapex / Revenue
3.6%
3.5%
Cash ConversionOCF / Net Profit
-0.29×
TTM Free Cash FlowTrailing 4 quarters
$-5.5M
$-9.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FEIM
FEIM
TKNO
TKNO
Q4 25
$-523.0K
$-462.0K
Q3 25
$1.2M
$-2.0M
Q2 25
$-155.0K
$-2.1M
Q1 25
$-3.6M
$-4.1M
Q4 24
$3.8M
$-936.0K
Q3 24
$-1.5M
$-2.1M
Q2 24
$7.5M
$-2.8M
Q1 24
$4.2M
$-6.6M
Free Cash Flow
FEIM
FEIM
TKNO
TKNO
Q4 25
$-1.1M
$-810.0K
Q3 25
$385.0K
$-2.4M
Q2 25
$-786.0K
$-2.3M
Q1 25
$-4.0M
$-4.3M
Q4 24
$3.3M
$-1.5M
Q3 24
$-1.8M
$-2.4M
Q2 24
$6.7M
$-3.0M
Q1 24
$3.9M
$-6.7M
FCF Margin
FEIM
FEIM
TKNO
TKNO
Q4 25
-6.6%
-8.1%
Q3 25
2.8%
-22.6%
Q2 25
-3.9%
-22.4%
Q1 25
-20.9%
-44.0%
Q4 24
20.8%
-16.2%
Q3 24
-11.8%
-25.0%
Q2 24
42.8%
-30.7%
Q1 24
28.4%
-71.8%
Capex Intensity
FEIM
FEIM
TKNO
TKNO
Q4 25
3.6%
3.5%
Q3 25
5.6%
3.7%
Q2 25
3.2%
2.0%
Q1 25
1.7%
2.1%
Q4 24
3.3%
6.1%
Q3 24
2.2%
3.5%
Q2 24
5.3%
1.2%
Q1 24
2.3%
1.2%
Cash Conversion
FEIM
FEIM
TKNO
TKNO
Q4 25
-0.29×
Q3 25
1.83×
Q2 25
-0.05×
Q1 25
-0.24×
Q4 24
1.44×
Q3 24
-0.60×
Q2 24
2.85×
Q1 24
32.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FEIM
FEIM

POC Revenue$14.8M86%
POT Revenue$2.3M13%

TKNO
TKNO

Lab Essentials$6.8M68%
Clinical Solutions$2.7M27%
Other$435.0K4%

Related Comparisons